HIV-associated lymphomas

Area of Science:

• Oncology
• Infectious Diseases
• Hematology

Background:

• Intermediate and high-grade non-Hodgkin lymphomas (NHL) with a B-cell phenotype are recognized as AIDS-defining illnesses.
• Individuals with HIV infection exhibit a markedly increased incidence of various lymphomas, including systemic NHL (over 100x), primary CNS NHL (over 3000x), and Hodgkin's disease (approx. 10x).

Purpose of the Study:

• To summarize the epidemiological and clinical characteristics of non-Hodgkin lymphomas and Hodgkin's disease in the context of HIV infection.
• To highlight the impact of highly active antiretroviral therapy (HAART) on potential treatment strategies for these malignancies.

Main Methods:

• Review of existing literature and epidemiological data concerning lymphoma incidence in HIV-infected populations.
• Analysis of clinical presentations, including extranodal and high-grade histologies, in HIV-associated lymphomas.

Main Results:

• HIV-infected individuals show substantially elevated risks for systemic NHL, primary CNS NHL, and Hodgkin's disease.
• Extranodal involvement and high-grade histologies are frequent findings in HIV-associated lymphomas.
• The advent of HAART may enable patients to undergo more aggressive treatment regimens.

Conclusions:

• Non-Hodgkin lymphomas and Hodgkin's disease represent significant oncological challenges in the HIV-infected population.
• Understanding these associations is crucial for timely diagnosis and management.
• Evolving treatment paradigms, influenced by HAART, offer potential for improved outcomes.